European medical device manufacturer Ypsomed AG is reorganising and expanding its Swiss site in Solothurn, creating additional jobs to handle expanded production of insulin injection systems.
This expansion of output was prompted by increased demand from a major unnamed customer and the need to increase output of pens used for self-medication insulin delivery, according to the firm.
It plans to boost its local workforce, creating 40 new full time posts at Solothurn in the project and production operations by the end of the industrialisation growth phase at the end of 2020.
In addition, Ypsomed, based at Burgdorf, north of Bern, Switzerland, intends to concentrate its growth in Solothurn, further to the north. The company will relocate 110 posts from its Diabetes Care division and adjacent business areas from the headquarters Burgdorf site to Solothurn.
The selfcare device specialist said it will transfer the employees to several office blocks in Solothurn that it already owns that it leased out up until the start of this year.
Employees being moved involve those in product management, mechanics, hard and software development, quality management and logistics. The Swiss market sales team, including customer service and call centre, is also due to transfer to Solothurn, Ypsomed announced.
Already, 34 personnel have switched sites under this programme and Ypsomed expects another 80 staff will make the change early next year.
Over the next three years, the firm intends to create a total of 300 new jobs in Switzerland, both at the Solothurn site and in Burgdorf which is situated in the country’s Bern canton.
In the past three years, Ypsomed has already hired 300 more workers nationally with 160 of them located in Solothurn. The company has a current workforce headcount at the northern site of 450, with 94 of those in the neighbouring community of Grenchen.
Ypsomed manufactures a wide range of injection pens, auto-injectors and infusion systems to administer liquid drugs. It serves pharmaceutical and biotechnology companies that develop, manufacture and market injectable medical therapies among its customers.
The group recorded a net profit of €45.4m on annual sales worth €406.6m in the year to 2018.
Today, the company has a total workforce of around 1,600, of whom about 1,089 are situated in Switzerland.